» Articles » PMID: 32884216

Mutations in SARS-CoV-2 Leading to Antigenic Variations in Spike Protein: A Challenge in Vaccine Development

Overview
Specialty Pathology
Date 2020 Sep 5
PMID 32884216
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

 The spread of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus has been unprecedentedly fast, spreading to more than 180 countries within 3 months with variable severity. One of the major reasons attributed to this variation is genetic mutation. Therefore, we aimed to predict the mutations in the spike protein (S) of the SARS-CoV-2 genomes available worldwide and analyze its impact on the antigenicity.  Several research groups have generated whole genome sequencing data which are available in the public repositories. A total of 1,604 spike proteins were extracted from 1,325 complete genome and 279 partial spike coding sequences of SARS-CoV-2 available in NCBI till May 1, 2020 and subjected to multiple sequence alignment to find the mutations corresponding to the reported single nucleotide polymorphisms (SNPs) in the genomic study. Further, the antigenicity of the predicted mutations inferred, and the epitopes were superimposed on the structure of the spike protein.  The sequence analysis resulted in high SNPs frequency. The significant variations in the predicted epitopes showing high antigenicity were A348V, V367F and A419S in receptor binding domain (RBD). Other mutations observed within RBD exhibiting low antigenicity were T323I, A344S, R408I, G476S, V483A, H519Q, A520S, A522S and K529E. The RBD T323I, A344S, V367F, A419S, A522S and K529E are novel mutations reported first time in this study. Moreover, A930V and D936Y mutations were observed in the heptad repeat domain and one mutation D1168H was noted in heptad repeat domain 2.  S protein is the major target for vaccine development, but several mutations were predicted in the antigenic epitopes of S protein across all genomes available globally. The emergence of various mutations within a short period might result in the conformational changes of the protein structure, which suggests that developing a universal vaccine may be a challenging task.

Citing Articles

The COVID-19 Vaccine in Clinical Trials: Where Are We Now?.

Jiang H, Li J, Zhang P, Huo X, Zhu F Infect Dis Immun. 2024; 1(1):43-51.

PMID: 38630107 PMC: 8057314. DOI: 10.1097/ID9.0000000000000003.


Towards a Safer Future: Enhancing Vaccine Development to Combat Animal Coronaviruses.

Si F, Yu R, Dong S, Chen B, Li C, Song S Vaccines (Basel). 2024; 12(3).

PMID: 38543964 PMC: 10974119. DOI: 10.3390/vaccines12030330.


Maiden Impact Factor to : An Encouragement for Editors and Authors.

Singh S J Lab Physicians. 2023; 15(3):327-328.

PMID: 37564224 PMC: 10411174. DOI: 10.1055/s-0043-1771389.


Translatability scoring in prospective and retrospective COVID drug development cases.

Wendler A, Wehling M Eur J Clin Pharmacol. 2023; 79(8):1051-1071.

PMID: 37278822 PMC: 10243273. DOI: 10.1007/s00228-023-03517-0.


Preclinical evaluation of ISH0339, a tetravalent broadly neutralizing bispecific antibody against SARS-CoV-2 with long-term protection.

Yang H, Chen Y, Jiang D, Feng X, Xu Y, Wei J Antib Ther. 2023; 6(2):97-107.

PMID: 37077474 PMC: 10108555. DOI: 10.1093/abt/tbad003.


References
1.
Wrapp D, Wang N, Corbett K, Goldsmith J, Hsieh C, Abiona O . Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020; 367(6483):1260-1263. PMC: 7164637. DOI: 10.1126/science.abb2507. View

2.
Bosch B, Rossen J, Bartelink W, Zuurveen S, de Haan C, Duquerroy S . Coronavirus escape from heptad repeat 2 (HR2)-derived peptide entry inhibition as a result of mutations in the HR1 domain of the spike fusion protein. J Virol. 2007; 82(5):2580-5. PMC: 2258948. DOI: 10.1128/JVI.02287-07. View

3.
Khailany R, Safdar M, Ozaslan M . Genomic characterization of a novel SARS-CoV-2. Gene Rep. 2020; 19:100682. PMC: 7161481. DOI: 10.1016/j.genrep.2020.100682. View

4.
Yuan M, Wu N, Zhu X, Lee C, So R, Lv H . A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. Science. 2020; 368(6491):630-633. PMC: 7164391. DOI: 10.1126/science.abb7269. View

5.
Liu S, Xiao G, Chen Y, He Y, Niu J, Escalante C . Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors. Lancet. 2004; 363(9413):938-47. PMC: 7140173. DOI: 10.1016/S0140-6736(04)15788-7. View